Humacyte, Inc.

USDC – Middle District of North Carolina

november 19, 2024

CLASS PERIOD: may 10, 2024 – october 17, 2024
LEAD PLAINTIFF DEADLINE: january 17, 2025

Principle Contacts

Jeffrey P. Campisi

JCampisi@kaplanfox.com

Laurence D. King

LKing@kaplanfox.com

HUMA Deadline to Lead in Securities Fraud Lawsuit is January 17, 2025 – Contact Kaplan Fox & Kilsheimer LLP

Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) on behalf of purchasers of Humacyte securities between May 10, 2024 and October 17, 2024 (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in Humacyte and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than January 17, 2025 to serve as a lead plaintiff for the purported class.  If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

According to the complaint, on August 9, 2024, after the market closed, Humacyte issued a press release announcing that the U.S. Food and Drug Administration (FDA) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication.”  The press release also states “[d]uring the course of the BLA review, the FDA has conducted inspections of our manufacturing facilities and clinical sites and has actively engaged with us in multiple discussions regarding our BLA filing.”

On this news, the Company’s stock price declined $1.29 per share, or 16.4%, to close at $6.62 per share on August 12, 2024, on unusually heavy volume.

The complaint further alleges that on October 17, 2024, during market hours, the FDA released a Form 483 concerning Humacyte’s Durham, North Carolina facility, which revealed a number of violations, including “‘no microbial quality assurance,’” “‘no microbial testing,’” and “inadequate ‘quality oversight.’”

On this news, the price of the Company’s stock price declined $0.95 per share, or 16.35%, to close at $4.86 per share on October 17, 2024, on unusually heavy volume.

WHY CONTACT KAPLAN FOX

Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.  With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.  Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients.  For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 329-8571

jcampisi@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com